favipiravir / Generic mfg. - LARVOL DELTA

Favipiravir as a potent inhibitor of Newcastle disease virus: in ovo efficacy, dose-dependent toxicity, and molecular insights into RNA polymerase inhibition. (PubMed, Vet World) - "These findings establish favipiravir as a promising antiviral candidate for ND virus control and potentially other RNA viruses of veterinary and One Health importance. Further in vivo and field-based studies are warranted to validate its safety, optimize dosing regimens, and evaluate large-scale applicability in poultry production."

Journal

Safety Profile of COVID-19 Medication in Patients with CKD: Renal and Hepatic Dysfunction Associated with Antiviral and Tocilizumab Use, a Single-Centre Experience (KIDNEY WEEK 2025) - "Methods We conducted a retrospective study on 1425 COVID-19-infected patients, who received anti-viral therapy, i.e., Favipiravir, lopinavir-Ritonavir, Remdesivir and tocilizumab. Conclusion CKD patients had a significantly higher incidence of renal function deterioration and an increase in AST. Nevertheless, these abnormal lab parameters must be considered with other risk factors, associated with severe covid-19-infection, thus COVID medicine shouldn't be denied to CKD patients"

Clinical • Chronic Kidney Disease • Hepatology • Infectious Disease • Liver Failure • Nephrology • Novel Coronavirus Disease • Renal Disease

Efficacy of favipiravir treatment for patients with severe fever with thrombocytopenia syndrome assessed with a historical control. (PubMed, Antimicrob Agents Chemother) - "Ferritin levels associated with hemophagocytosis severity were significantly different between the FPV and BSC groups on Days 3 to 9 after matching. No concerning serious adverse events were observed in the FPV group.This interventional study has been registered with the Japan Registry of Clinical Trials as jRCT2080223816."

Journal • Hematological Disorders • Infectious Disease • Thrombocytopenia

Antiviral strategies against H5N1: current options and emerging therapeutics. (PubMed, Infection) - "This article provides a comprehensive, up-to-date overview of antiviral agents with established or investigational activity against H5N1, including both globally approved drugs and regionally licensed compounds, such as arbidol and triazavirin in Russia and laninamivir and favipiravir in Japan...The recent regulatory approvals of onradivir, suraxavir marboxil, and ZX-7101A in China are highlighted, along with emerging antivirals in advanced development...Challenges persist around resistance monitoring, access to novel therapies, and regulatory harmonization. Expanding the antiviral armamentarium through accelerated evaluation and integration of both traditional and innovative compounds will be essential to pandemic preparedness and effective H5N1 outbreak response."

Journal • Review • Infectious Disease • Influenza • Respiratory Diseases

Longitudinal 18F-FDG-PET/CT as a Prognostic Tool for Influenza-induced Lung Inflammation and Therapy Response in Mice (ASTMH 2025) - "Immunocompetent mice were infected with a lethal dose of influenza A /H1N1 PR8 and subsequently treated with either antiviral agents (baloxavir or favipiravir) or vehicle control. Most importantly, lung FDG correlates with inflammatory markers in the lung but not with viral burden in the tissue, confirming that lung FDG uptake reflects the inflammatory processes triggered by influenza and the reduction of inflammation resulting from effective treatment. By quantifying inflammatory responses, FDG-PET offers a valuable tool for rapid preclinical assessment of novel or repurposed influenza therapeutics, potentially acceleration drug development."

FDG PET • Preclinical • Infectious Disease • Inflammation • Influenza • Pneumonia • Pulmonary Disease • Respiratory Diseases

Synthetic genomics-based generation of the tick-borne encephalitis virus Siberian subtype prototype strain and E51K-attenuated variant for vaccine development and antiviral screening. (PubMed, Virol Sin) - "Using this reporter system, we demonstrated that favipiravir possesses antiviral activity against TBEV, with inhibitory concentrations within a pharmacologically relevant range. In conclusion, synthetic genomics enabled the generation of a reference TBEV strain to replenish Kazakhstan's collections. The E51K mutation enhances viral replication in vitro while attenuating pathogenicity in vivo, and the derived reporter virus is suitable for antiviral compound screening."

Journal • CNS Disorders

First therapeutic drug monitoring of experimental favipiravir in Borna disease virus 1 (BoDV-1) encephalitis patients reveals significant gaps in antiviral treatment: a pilot investigation. (PubMed, Eur J Med Res) - "In conclusion, monitoring experimental FPV therapy in BoDV-1 encephalitis is feasible and should be performed continuously. Future prospective in-depth (multicenter) studies should include more patients and focus on dose-finding, dose-response relationships, and define a therapeutic index to improve outcomes of this so far nearly uniformly fatal disease."

Journal • CNS Disorders

Conserved Filovirus Proteins as Targets of Broad-Spectrum Antivirals. (PubMed, bioRxiv) - "Conserved filovirus sites targeted for broad-spectrum antivirals.Structural modeling identifies key antiviral binding sites.Viral internal proteins are crucial targets for inhibition.Remdesivir validates conserved polymerase as a druggable target.Study highlights need for pan-filovirus drug screening."

Journal • Ebola Virus Disease • Hematological Disorders • Infectious Disease

Recent Advances in Therapeutics for Severe Fever with Thrombocytopenia Syndrome Virus. (PubMed, Viruses) - "The nucleotide analogues (favipiravir, 4'-fluorouridine diphosphate prodrug VV261) have shown clinical potential. Calcium channel blockers (nifedipine, etc.) block virus invasion by inhibiting calcium influx...In addition, the low bioavailability of small-molecule drugs, the obstacles to industrial-scale production of antibody-based therapies, and the lack of Phase III clinical evidence severely restrict their clinical translation. Future research should focus on exploring viral replication mechanisms, developing drugs against key viral proteins, and designing multi-target combination therapies and novel drug delivery systems."

Journal • Review • Hematological Disorders • Thrombocytopenia

In Vivo Efficacy of a Broad-Spectrum Antiviral Combination Against Yellow Fever in a Hamster Model. (PubMed, Pathogens) - "Herein, we describe the evaluation of 6-MMPr, a de-novo-purine-nucleotide biosynthesis inhibitor, as a potentiator for enhanced activity of the broad-spectrum antiviral drug favipiravir in a hamster model of yellow fever...The initiation of treatment two days after virus challenge was also effective in improving survival when compared with monotherapy. Our results demonstrate the safety and efficacy of such a combination either as a preventive or delayed treatment."

Journal • Preclinical

Development and Validation of a Novel Isocratic RP-HPLC Method Using AQbD Approach for the Quantification of Favipiravir. (PubMed, Eur J Pharm Sci) - "AQbD is a useful tool to replace existing traditional methods for the optimization of a green, validated RP-HPLC method, for the routine analysis and quality control of FAV."

Journal

Delayed Hematologic Recovery After BCMA CAR-T Is Associated with Progressive Loss of Endogenous T Cell Diversity After CAR-T Infusion (IMS 2025) - "We previously reported (Avigan et al, ASH 2024 abstract 3329) that patients with prolonged cytopenias beyond day 100 have decreased survival and persistently increased inflammatory markers after CAR-T...We therefore hypothesized that patients with delayed hematologic recovery after CAR-T would show a distinct endogenous T cell recovery pattern, which may contribute to ongoing hematotoxicity. We reviewed patients treated with cilta-cel with available NGS of their T cell receptor (TCR) repertoire within 2 years and prior to relapse... Patients with delayed hematologic recovery after CAR-T showed increased TCR clonal dominance and decreased diversity in endogenous T cell populations, with a marked disruption in diversity after 6 months. Our current efforts are aimed at understanding and characterizing the role of native T cell diversity in driving inflammatory dysregulation, hematologic toxicity, and disease response after CAR-T."

IO biomarker • Hematological Disorders • Hematological Malignancies • Multiple Myeloma

An orally available 4'-fluorouridine prodrug inhibits SFTSV and LCMV infection. (PubMed, J Virol) - "In lethal rodent models, once-daily oral administration of VV251 at low doses (10 mg/kg for SFTSV; 1 mg/kg for LCMV) achieves complete protection (100% survival), matching the efficacy of T-705 at 300 mg/kg...Here, we report that VV251 hydrochloride salt (VV251), an optimized oral prodrug derivative of 4'-fluorouridine (4'-FlU, EIDD-2794), shows significant efficacy against severe fever with thrombocytopenia syndrome virus and lymphocytic choriomeningitis virus infections, with inhibitory activity in cell culture and protective effects in lethal animal models. Building on the established broad-spectrum antiviral activity of 4'-FlU against multiple high-consequence pathogens (including severe acute respiratory syndrome coronavirus 2, respiratory syncytial virus, Lassa virus, and Junin virus), VV251 emerges as a promising next-generation oral antiviral candidate, offering an orally available therapeutic option to combat these formidable pathogens."

Journal • CNS Disorders • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Thrombocytopenia

AGILE (Early Phase Platform Trial for COVID-19) (clinicaltrials.gov) - P1/2 | N=600 | Recruiting | Sponsor: University of Liverpool | Active, not recruiting ➔ Recruiting | Trial completion date: Jul 2025 ➔ Oct 2026 | Trial primary completion date: Jul 2025 ➔ Oct 2026

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Increasing Occurrence of Marburg Virus Outbreaks in Africa: Risk Assessment for Public Health. (PubMed, Microb Biotechnol) - "Compounds included galidesivir, an adenosine nucleoside analogue; favipiravir, a synthetic guanine base analog; remdesivir, an injectable; and obeldesivir, an oral prodrug which are intracellularly metabolised to an adenosine triphosphate nucleotide analog; small interfering RNA drugs that target short segments of the MARV nucleoprotein NP mRNA; and a human neutralising monoclonal antibody directed against MARV glycoprotein. The African CDC has attributed an upper tier risk attribution to MVD when comparing 18 pathogens. For the moment, the short human MARV infection chains make large international outbreaks unlikely, but viral genome analysis in future outbreaks for transmission mutants is warranted."

Journal • Review • Infectious Disease

Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model. (PubMed, J Antimicrob Chemother) - "Placental transfer was high for the nucleoside analogue favipiravir, while it was low for molnupiravir and low for the protease inhibitor nirmatrelvir but increased by ritonavir. Clinical data are required to confirm the placental transfer and determine the safety of COVID antivirals in pregnancy."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease

Design and Synthesis of Potent Ridaifen Analogues: Evaluation as Anticancer, 20S Proteasomal Inhibitors, and Antiebola Virus Agents through In vitro and In Silico Studies. (PubMed, ChemMedChem) - "Most of the analogs showed pan activity toward different cancer cell lines, and compound 20 was more potent than tamoxifen. Compound 20 showed submicromolar IC50 values for CT-L and PGPH activities, indicating that it mediates its cytotoxic activity via proteasomal inhibition. Selected compounds were tested against Ebolavirus, and compound 36 showed the highest antiviral activity, surpassing the EC50 of the reference compound favipiravir."

Journal • Preclinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Solid Tumor • Targeted Protein Degradation

A rare case of cutaneous vascular phenomena and fulminant cardiac involvement in paediatric multisystem inflammatory syndrome in children following asymptomatic COVID-19 exposure in a 7-year-old child. (PubMed, Cardiol Young) - "Milrinone and noradrenaline were promptly started for hemodynamic support. Intravenous immunoglobulin, methylprednisolone, favipiravir, and anakinra were started for his treatment...On the 10th day of hospitalisation, the patient was discharged from the hospital, marking a successful recovery from a complex and severe case. This successful recovery serves as a beacon of hope in the management of multisystem inflammatory syndrome in children."

Journal • Cardiovascular • Hypotension • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases • Thrombocytopenia

Favipiravir-induced fluorescent nails and hair: A rare phenomenon. (PubMed, Med J Armed Forces India) - No abstract available

Journal

Clinical Management Strategies for Severe Fever with Thrombocytopenia Syndrome Induced by Tick Bites: A Case Report and Literature Review. (PubMed, Am J Case Rep) - "Despite aggressive therapy, including intravenous immunoglobulin (IVIG), favipiravir, doxycycline, meropenem, and platelet transfusions, progressive multiorgan failure manifested as metabolic acidosis (pH 7.24, lactate 6.57 mmol/L), hepatorenal and kidney dysfunction (ALT 665.2 U/L, AST 7764 U/L, creatinine 191 umol/L), hypoxemic respiratory failure (PaO₂/FiO₂ 160), and neurological decline (GCS 10). Despite 72 hours of aggressive critical care interventions, the patient died due to refractory multiorgan failure secondary to viral sepsis. CONCLUSIONS This case is a stark reminder of the rapid progression and severe nature of fever with thrombocytopenia syndrome associated with tick bites, emphasizing the critical need for individualized treatment strategies tailored to the clinical classification of the illness, particularly in severe cases that might involve neurological complications."

Journal • Review • CNS Disorders • Cough • Critical care • Hematological Disorders • Infectious Disease • Leukopenia • Metabolic Disorders • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • Thrombocytopenia

A quality-by-design optimized LC method for navigating degradation kinetics and quantification of favipiravir in the presence of degradation products and manufacturing impurities. (PubMed, BMC Chem) - "The proposed method was evaluated for its greenness and blueness to demonstrate its ecological safety and practicality, scoring 0.65 in the Analytical Greenness (AGREE) metric and 85.00 on the Blue Applicability Grade Index (BAGI). It is the first sustainable method developed using the Quality-by-Design to profile favipiravir together with its degradation products and impurities simultaneously."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Electrochemical sensing platform for simultaneous quantification of antiviral drugs favipiravir and molnupiravir using α-MnO2@PDDA nanocomposites (ACS-Fall 2025) - "The sensor exhibited excellent electrochemical performance, offering high sensitivity and selectivity. Validation studies confirmed its reliability in detecting FAV and MOL in commercial tablets and whole human blood samples, with results comparable to those obtained using UV-visible spectrophotometry, demonstrating its potential for clinical, pharmaceutical, and healthcare applications."

Infectious Disease • Novel Coronavirus Disease

Novel and repurposed antiviral molecules for arbovirus infections with epidemic Potential: A systematic review. (PubMed, New Microbes New Infect) - "Favipiravir, ribavirin, and sofosbuvir demonstrated viremia reduction and symptoms improvement in vitro and in vivo experiments...Montelukast and doxycycline exhibited anti-inflammatory effects, contributing to improved clinical outcomes... Currently, there are no studies in humans demonstrating effective treatments against arboviral infections. Although some molecules have shown efficacy in reducing viral titters, further clinical evaluation of promising candidates and the exploration of combination therapies targeting viral replication and host immune-response are needed."

Journal • Review • Chikungunya • Dengue Fever • Infectious Disease

Study on the treatment of Severe Fever with Thrombocytopenia Syndrome with Faviravir Tablets (ChiCTR) - P4 | N=200 | Not yet recruiting | Sponsor: The Second Hospital of Anhui Medical University; The Second Hospital of Anhui Medical University

New P4 trial • Hematological Disorders • Thrombocytopenia

Re-evaluating a single-arm trial of favipiravir for severe fever with thrombocytopenia syndrome in Japan: A proposal to use real-world data as external controls. (PubMed, PLoS Negl Trop Dis) - No abstract available

Journal • Real-world evidence • Hematological Disorders • Thrombocytopenia